EUVIMEDEUVIMED entdecken
Crossref

Dual, Postsynaptic 5-HT2B Antagonist and 5-HT1A Agonist Approach to the Treatment of METH/MDMA Addiction and Related Problems. Part 2. Proof of Concept.

Receptors & Clinical Investigation · 2014

DOI: 10.14800/rci.106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Receptors & Clinical Investigation, 2014.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2014). Dual, Postsynaptic 5-HT2B Antagonist and 5-HT1A Agonist Approach to the Treatment of METH/MDMA Addiction and Related Problems. Part 2. Proof of Concept. Receptors & Clinical Investigation. https://doi.org/10.14800/rci.106

Vancouver

Dual, Postsynaptic 5-HT2B Antagonist and 5-HT1A Agonist Approach to the Treatment of METH/MDMA Addiction and Related Problems. Part 2. Proof of Concept. Receptors & Clinical Investigation. 2014. doi:10.14800/rci.106

BibTeX
@article{euvimed2014,
  title = {Dual, Postsynaptic 5-HT2B Antagonist and 5-HT1A Agonist Approach to the Treatment of METH/MDMA Addiction and Related Problems. Part 2. Proof of Concept},
  journal = {Receptors & Clinical Investigation},
  year = {2014},
  doi = {10.14800/rci.106}
}
Kostenlos starten →